Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

This week in Drug Discovery (27-31 July 2026) 

Published

on

""

News round-up for 27-31 July by Megan Thomas, Content Team at DDW. 

This week’s news roundup centres around investment, innovation and strategic growth, which have dominated this week’s headlines. Across the drug discovery sector, companies have secured funding, expanded R&D capabilities and accelerated the adoption of AI-driven technologies. In addition, DDW has announced the preliminary speaker lineup for the Drug Discovery Innovators & Investors (DDII) Digital Forum.

The top stories: 

Drug Discovery Innovators & Investors Digital Forum announces speaker lineup

We are pleased to announce the preliminary speaker lineup for the Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place 30 September 2026. Supported by DDW, the forum brings together senior leaders from biotech, pharma, academia, and investment to explore the opportunities and challenges shaping early-stage drug discovery.

Read more…

Qureight closes $20 million Series B financing

Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases.

Read more… 

Carterra at centre of US$7bn antibody discovery market

In a report published on July 16 2026, titled Lab-in-the-Loop: AI Rewires Antibody Discovery, Unlocking a US$7 billion LST Opportunity, “Lab-in-the-Loop” (LitL) is described as an emerging approach in which AI models propose candidate antibody sequences, wet lab experiments test them, and the resulting data is fed back into the AI to improve the next round of designs. This transforms what was once a slow, serial discovery process into a faster, guided one.

Read more… 

GSK plans new flagship R&D centre and £400m investment in UK

GSK has announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline.

Read more… 

New index reveals Eli Lilly as the top ranked company

Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.

Read more… 

The post This week in Drug Discovery (27-31 July 2026)  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read